Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 492,400 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 492,400 shares of the stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the transaction, the insider owned 812,058 shares in the company, valued at approximately $17,775,949.62. This trade represents a 37.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Trading Down 0.1%

NASDAQ:ADPT opened at $22.52 on Wednesday. Adaptive Biotechnologies Corporation has a 12 month low of $9.96 and a 12 month high of $23.15. The company has a market cap of $3.60 billion, a PE ratio of -68.24 and a beta of 2.07. The company has a 50 day simple moving average of $18.88 and a two-hundred day simple moving average of $16.51.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.20) EPS. Research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies during the fourth quarter valued at $28,000. EverSource Wealth Advisors LLC grew its holdings in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares during the period. KBC Group NV purchased a new stake in Adaptive Biotechnologies in the first quarter worth about $45,000. Assetmark Inc. increased its position in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $51,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ADPT has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Morgan Stanley raised their target price on Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. BTIG Research restated a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, July 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.83.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.